[
    {
        "pregunta": "1. What are the recommendations for patients with RMD regarding the use of combined estrogen-progestin contraceptives?",
        "respuesta": "The recommendation for patients with RMD regarding the use of combined estrogen-progestin contraceptives is as follows:\n\nIt is advised not to use combined estrogen-progestin contraceptives if the patient has positive aPL (antiphospholipid antibodies). Instead, the use of an IUD (intrauterine device) or progestin-only pill is recommended for these individuals.\n\nIf you have any more questions or need further information, please let me know.",
        "contexto": [
            "|Effective|Progestin-only pill (daily)|Safe in all women with RMD; higher rate of breakthrough bleeding than with combined contraceptives; must take same time every day for efficacy|5–8|\n| |DMPA (IM injection every 12 weeks)|Safe in most women with RMD; exceptions: positive aPL, at high risk for OP|3|\n| |Combined estrogen and progesterone pill (daily)|Safe in most women with RMD; exceptions: positive aPL, very active SLE|5–8|",
            "<p>|Topic|Recommendation|Strength|\n|---|---|---|\n|Contraception|All RMD|GPS|\n| |Contraception/pregnancy discussion early and regularly; choose contraception based on safety, efficacy, and patient preference| |\n| |Use barrier methods if unable to use other methods|GPS|\n| |Use emergency contraception if necessary [6]|Strong|\n| |Women receiving immunosuppressive medications: Use IUD if desired [7]|Strong|\n| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|",
            "| |Avoid transdermal estrogen-progestin patch [2B]|Conditional|\n| |SLE with negative aPL and moderate-to-high disease activity: Use progestin-only contraceptives or IUD [2C]|Strong|\n|Positive aPL|Do not use combined estrogen-progestin contraceptives [3]; use IUD or progestin-only pill [4]|Strong|\n|Assisted reproductive technology|All RMD|GPS|\n| |Stable disease and negative aPL: Proceed with assisted reproductive technology: IVF if pregnancy-compatible medications [24]|Strong|",
            "<h1>Table 1. Safety and efficacy of various contraceptive methods in women with RMD*</h1>",
            "and counsel their patients about contraception, pregnancy and lactation (including medications), assisted reproductive technology (ART), fertility preservation, and hormone replacement therapy (HRT), and they must collaborate with specialists in the fields of obstetrics-gynecology, maternal-fetal medicine, and reproductive endocrinology and infertility. Pregnancy in women with RMD may lead to serious maternal or fetal adverse outcomes; accordingly, contraception, tailored to the individual"
        ]
    },
    {
        "pregunta": "2. What is the preferred approach for patients at risk for osteoporosis in terms of contraceptive options?",
        "respuesta": "The preferred approach for patients at risk for osteoporosis in terms of contraceptive options is to avoid using Depo-Medroxyprogesterone Acetate (DMPA) as a contraceptive method. Instead, it is recommended to choose contraception based on safety, efficacy, and patient preference. For women at risk for osteoporosis, the use of an intrauterine device (IUD) is advised if desired. It is important to have discussions about contraception and pregnancy early and regularly with healthcare providers to make informed decisions regarding the most suitable contraceptive option based on individual circumstances.\n\nIf you have any more questions or need further information, please let me know.",
        "contexto": [
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we",
            "initial therapy for those at very high risk for fracture based on BMD and vertebral fracture prevention superiority compared to anti-resorptives in patients with very high risk postmenopausal OP. Of note, abaloparatide and ROM are not approved in GIOP, and we recognize it may be difficult to access these medications for GIOP. The panel specifically noted that the potential harms of RAL (venous thromboembolism [VTE] and fatal stroke) and ROM (major myocardial infarction, stroke, and death) would",
            "<p>|Topic|Recommendation|Strength|\n|---|---|---|\n|Contraception|All RMD|GPS|\n| |Contraception/pregnancy discussion early and regularly; choose contraception based on safety, efficacy, and patient preference| |\n| |Use barrier methods if unable to use other methods|GPS|\n| |Use emergency contraception if necessary [6]|Strong|\n| |Women receiving immunosuppressive medications: Use IUD if desired [7]|Strong|\n| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|\n| |Women receiving MMF: Use IUD or 2 other methods together [11]|Conditional|\n| |RMD without SLE or aPL: Use highly effective or effective methods† [1]|Strong|\n| |Highly effective methods preferred to effective methods [1A]|Conditional|\n|SLE|SLE with negative aPL and low/stable disease activity: Use highly effective or effective methods† [2]|Strong|\n| |Highly effective methods preferred to effective methods [2A]|Conditional|"
        ]
    },
    {
        "pregunta": "3. How should stress-dose glucocorticoids be administered during vaginal delivery according to the guideline?",
        "respuesta": "The guideline does not recommend treating with stress-dose glucocorticoids at the time of vaginal delivery. However, the guideline does conditionally recommend such treatment for surgical (cesarean) delivery. If you have any more questions or need further information, please let me know.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "of prednisone or nonfluorinated equivalent) during pregnancy if clinically indicated. We strongly recommend tapering higher doses of nonfluorinated glucocorticoids to <20 mg daily of prednisone, adding a pregnancy-compatible glucocorticoid-sparing agent if necessary. Although there are only minimal data regarding prolonged treatment with low-dose glucocorticoids during pregnancy, we conditionally recommend against routine administration of stress-dose glucocorticoids at the time of vaginal",
            "NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2 trimesters, due to lack of data on cyclooxygenase 2-specific inhibitors. Nonfluorinated glucocorticoids should be used when needed, but substitution of steroid-sparing pregnancy-compatible immunosuppressive therapy is desirable when high-dose or prolonged use is required. We conditionally recommend continuing low-dose glucocorticoid treatment (≤10 mg daily of prednisone or nonfluorinated equivalent) during pregnancy if clinically",
            "shown on echocardiography, we conditionally recommend treatment with oral dexamethasone 4 mg daily. If CHB (without other cardiac inflammation) is present, we conditionally recommend against treating with dexamethasone. Fluorinated glucocorticoids, such as dexamethasone and betamethasone, cross the placenta; low-to-moderate-dose nonfluorinated glucocorticoids, such as prednisone and prednisolone, are largely metabolized before they reach the fetus. Whether dexamethasone given for fetal first-or",
            "|Continue regular low-dose prednisone [201]|Conditional| |\n|Taper high-dose prednisone with addition of pregnancy-compatible drug if needed|Strong| |\n|Stress-dose steroid at delivery: do not treat for vaginal delivery, do treat for cesarean delivery|Conditional| |\n|Breastfeeding|Encourage breastfeeding and maintain disease control with compatible medications if possible|GPS|\n|Compatible medications:|HCQ, infliximab, etanercept, adalimumab, golimumab, certolizumab, rituximab|Strong|"
        ]
    },
    {
        "pregunta": "4. What is the recommended approach for continuing tumor necrosis factor inhibitor therapy during pregnancy?",
        "respuesta": "The guideline conditionally recommends continuing tumor necrosis factor (TNF) inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy. However, it recommends discontinuing treatment with rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, and ustekinumab once the pregnancy is confirmed. If disease control cannot be achieved with compatible pregnancy medications, physicians and patients should have a discussion regarding the potential risks and benefits of continuing treatment. There are no specific recommendations for tofacitinib, baricitinib, or apremilast due to a lack of data on their use during pregnancy.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible",
            "NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2 trimesters, due to lack of data on cyclooxygenase 2-specific inhibitors. Nonfluorinated glucocorticoids should be used when needed, but substitution of steroid-sparing pregnancy-compatible immunosuppressive therapy is desirable when high-dose or prolonged use is required. We conditionally recommend continuing low-dose glucocorticoid treatment (≤10 mg daily of prednisone or nonfluorinated equivalent) during pregnancy if clinically",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |",
            "of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at"
        ]
    },
    {
        "pregunta": "5. How do biologic therapies vary in terms of placental transfer and fetal exposure during pregnancy?",
        "respuesta": "Biologic therapies vary in terms of placental transfer and fetal exposure during pregnancy. Most biologic therapies for rheumatic and musculoskeletal diseases contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester. Therefore, the majority of these biologic therapies are considered compatible with pregnancy in the periconception period. However, there are limited data on the compatibility of other biologics with pregnancy. Non-TNF inhibitor IgG-based molecules are generally considered compatible in the periconception period but should be discontinued during pregnancy as they may cross the placenta in later stages. It is crucial to consult with healthcare providers to make informed decisions about the use of biologic therapies during pregnancy based on individual circumstances.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at",
            "is whether his medication is present in seminal fluid and can transfer through vaginal mucosa, cross the placenta, and be teratogenic. In fact, post-conception exposure of the embryo or fetus is likely minimal,  as seminal concentrations of medications and volumes transferred are small In the absence of adequate data regarding paternal exposure for most medications used for RMD, we developed recommendation statements when 1) at least some data on paternal exposure were available, 2) accumulated",
            "half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum",
            "immunization, and for this reason, the AAP recommends delaying rotavirus vaccination for 12 months after any in utero exposure to biologic DMARDs (except for certolizumab, which does not cross the placenta) The literature review identified no data on the effect of in utero rituximab exposure on later vaccine responses. Rituximab is a chimeric IgG1 molecule that can cross the placenta, and it has been associated with low or absent B lymphocyte levels in newborns who were exposed during the"
        ]
    },
    {
        "pregunta": "6. What is the panel's recommendation regarding the use of non-TNF inhibitor IgG-based molecules during the periconception period and pregnancy?",
        "respuesta": "The panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). It is crucial to consult with healthcare providers to make informed decisions about the use of these biologic therapies during pregnancy based on individual circumstances.",
        "contexto": [
            "of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at",
            "half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum",
            "periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible",
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "and pamidronate were suggested as alternatives for the treatment of patients with active disease and contraindications to TNFi, while the current recommendations suggest use of secukinumab or ixekizumab in most of these cases (except patients with high risk of infections). In cases of failure of TNFi, the 2015 guidelines included a conditional recommendation for a trial of a second TNFi and against use of a non-TNFi biologic, whereas the current guidelines differentiate treatment"
        ]
    },
    {
        "pregunta": "7. How should treatment with rituximab be managed in women trying to conceive and during pregnancy?",
        "respuesta": "The panel conditionally recommends continuing treatment with rituximab while a woman is trying to conceive, and continuing rituximab during pregnancy is also conditionally recommended if severe life-or organ-threatening maternal disease warrants it. However, rituximab should be discontinued once the woman is found to be pregnant. It is crucial to have discussions with healthcare providers to carefully weigh the risks of these medications versus the risks of uncontrolled disease during pregnancy and make informed decisions based on individual circumstances.",
        "contexto": [
            "pregnancy, the physician and patient should discuss and weigh the possible risks from these medications versus the risks of uncontrolled disease during pregnancy. We conditionally recommend continuing treatment with rituximab while a woman is trying to conceive, and we conditionally recommend continuing rituximab during pregnancy if severe life-or organ-threatening maternal disease so warrants. Dosing in the second half of pregnancy puts the fetus at high risk of having minimal B cells at",
            "periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible",
            "treatment with rituximab over switching to cyclophosphamide for remission re-induction. Re-induction of remission with rituximab is favored over cyclophosphamide treatment to minimize toxicity. However, the duration of remission prior to the onset of relapse should be examined. Cyclophosphamide should be considered if a severe relapse occurred quickly after rituximab treatment, or if cardiac involvement is present (see ungraded position statement and recommendation on this topic).",
            "randomized controlled trial Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction. Multiple factors can influence whether rituximab or cyclophosphamide treatment (IV or oral) is used, such as time since last rituximab infusion and cumulative cyclophosphamide dose.",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |"
        ]
    },
    {
        "pregunta": "8. What is the guideline's stance on the use of small-molecule agents like tofacitinib, baricitinib, and apremilast during pregnancy?",
        "respuesta": "The guideline does not offer specific recommendations regarding the use of small-molecule agents like tofacitinib, baricitinib, and apremilast during pregnancy. The Voting Panel elected not to provide guidance on these drugs due to a lack of available evidence. Therefore, it is recommended to consult with healthcare providers to make informed decisions about the use of these medications during pregnancy based on individual circumstances.",
        "contexto": [
            "half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |",
            "| Anakinra, belimumab, abatacept, tocilizumab, secukinumab, ustekinumab | + (Discontinue at conception)                                      | + (Discontinue during pregnancy)                                | Expect minimal transfer due to large molecular size, but no available data |",
            "| Thalidomide (discontinue 4 weeks prior to attempted conception) | Abatacept, Apremilast, Baricitinib, Belimumab, Secukinumab, Tocilizumab, Tofacitinib, Ustekinumab |</p>",
            "|---|---|\n|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy.|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy.|\n|13. Add apremilast to current OSM therapy over switching to apremilast (PICO 22b)|Low (83, 84, 108)|"
        ]
    },
    {
        "pregunta": "9. What are the recommendations for breastfeeding while on RMD medications such as HCQ, colchicine, and TNF inhibitors?",
        "respuesta": "The recommendations for breastfeeding while on RMD medications such as HCQ, colchicine, and TNF inhibitors are as follows:\n\n- Strongly recommend treatment with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors as compatible with breastfeeding.\n- Strongly recommend prednisone <20 mg daily (or equivalent nonfluorinated glucocorticoid) as compatible with breastfeeding, but strongly recommend delaying breastfeeding or discarding breast milk accumulated in the 4 hours following glucocorticoid administration with doses of prednisone ≥20 mg a day (or equivalent).\n- Conditionally recommend treatment with azathioprine/6-mercaptopurine, calcineurin inhibitors, NSAIDs, and the non-TNF inhibitor biologic agents (anakinra, rituximab, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab) as compatible with breastfeeding.\n- Strongly recommend against the use of CYC, leflunomide, MMF, and thalidomide while breastfeeding.\n- Conditionally recommend against the use of MTX while breastfeeding.\n\nIf you have any more questions or need further information, please let me know.",
        "contexto": [
            "breastfeeding. The benefits of breastfeeding are numerous Infant serum levels of drugs ingested by the mother depend on multiple variables and are a function of drug concentration in breast milk, quantity of breast milk ingested, and drug absorption through the infant's gastrointestinal tract. Premature infants Fortunately, many RMD medications may be initiated or continued during lactation. We strongly recommend treatment with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors",
            "with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors as compatible with breastfeeding We also recommend prednisone <20 mg daily (or equivalent nonfluorinated glucocorticoid) as compatible with breastfeeding, but strongly recommend that with doses of prednisone ≥20 mg a day (or equivalent), women delay breastfeeding or discard breast milk accumulated in the 4 hours following glucocorticoid administration. We conditionally recommend treatment with azathioprine/6-mercaptopurine,",
            "We conditionally recommend treatment with azathioprine/6-mercaptopurine, calcineurin inhibitors, NSAIDs and the non-TNF inhibitor biologic agents (anakinra, rituximab, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab) as compatible with breastfeeding We strongly recommend against use of CYC, leflunomide, MMF, and thalidomide while breastfeeding. We conditionally recommend against use of MTX while breastfeeding. Despite minimal passage of MTX into breast milk, especially with",
            "referral to a maternal-fetal medicine specialist, pregnancy medication specialist, or genetics counselor as standard good practice. We strongly recommend HCQ, azathioprine/6mercaptopurine, colchicine, and sulfasalazine, medications commonly used for RMD, as compatible for use throughout pregnancy We conditionally recommend calcineurin inhibitors (tacrolimus and cyclosporine) and NSAIDs as compatible for use during pregnancy We conditionally recommend discontinuation of NSAIDs pre-conception if",
            "compatibility of many rheumatology medications both with lactation and with paternal use. The rheumatologist's familiarity with drug safety during these periods is important to maintain disease control and minimize mother and infant risk. Fertility and postmenopausal issues are not uncommon in RMD patients. Recommendations regarding ART reflect a growing demand among patients with RMD for fertility therapies. Oocyte freezing is now widely available The strength of evidence on reproductive"
        ]
    },
    {
        "pregunta": "10. How should breastfeeding be managed for women taking prednisone at different dose levels?",
        "respuesta": "Breastfeeding should be managed for women taking prednisone at different dose levels as follows:\n\n- For prednisone <20 mg daily (or equivalent nonfluorinated glucocorticoid), it is considered compatible with breastfeeding.\n- For doses of prednisone ≥20 mg a day (or equivalent), it is strongly recommended that women delay breastfeeding or discard breast milk accumulated in the 4 hours following glucocorticoid administration.\n\nIf you have any more questions or need further information, please let me know.",
        "contexto": [
            "with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors as compatible with breastfeeding We also recommend prednisone <20 mg daily (or equivalent nonfluorinated glucocorticoid) as compatible with breastfeeding, but strongly recommend that with doses of prednisone ≥20 mg a day (or equivalent), women delay breastfeeding or discard breast milk accumulated in the 4 hours following glucocorticoid administration. We conditionally recommend treatment with azathioprine/6-mercaptopurine,",
            "|Continue regular low-dose prednisone [201]|Conditional| |\n|Taper high-dose prednisone with addition of pregnancy-compatible drug if needed|Strong| |\n|Stress-dose steroid at delivery: do not treat for vaginal delivery, do treat for cesarean delivery|Conditional| |\n|Breastfeeding|Encourage breastfeeding and maintain disease control with compatible medications if possible|GPS|\n|Compatible medications:|HCQ, infliximab, etanercept, adalimumab, golimumab, certolizumab, rituximab|Strong|",
            "| Prednisone                               | + (Taper to &lt;20 mg/day)                                           | + (Taper to &lt;20 mg/day)                                        | After a dose &gt;20 mg, delay breastfeeding for 4 hours            |\n| Cyclosporine, tacrolimus                 | + (Monitor blood pressure)                                        | + (Monitor blood pressure)                                     | + (Low transfer)                                               |",
            "breastfeeding. The benefits of breastfeeding are numerous Infant serum levels of drugs ingested by the mother depend on multiple variables and are a function of drug concentration in breast milk, quantity of breast milk ingested, and drug absorption through the infant's gastrointestinal tract. Premature infants Fortunately, many RMD medications may be initiated or continued during lactation. We strongly recommend treatment with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors",
            "of prednisone or nonfluorinated equivalent) during pregnancy if clinically indicated. We strongly recommend tapering higher doses of nonfluorinated glucocorticoids to <20 mg daily of prednisone, adding a pregnancy-compatible glucocorticoid-sparing agent if necessary. Although there are only minimal data regarding prolonged treatment with low-dose glucocorticoids during pregnancy, we conditionally recommend against routine administration of stress-dose glucocorticoids at the time of vaginal"
        ]
    }
]